


Biological agents in resistant tumors to first generation agents in NSCLC

Guy Berchem MD, PhD

Centre Hospitalier de Luxembourg Luxembourg Institute of Health

Oncogene addiction in NSCLC (ADC)

1st line situation +/- 70% are oncogene addicted




Skoulidis, F., Heymach, J.V. Nat Rev Cancer 19, 495-509 (2019).

Biological agents in resistant tumors to first generation agents in NSCLC

In general, how to procede...


- Classical TKI based treatment of oncogen addicted NSCLC
- What to do in case of (ineviteable) progression
 - Rebiopsy + NGS
 - Treatment of oligometastatic progressing disease
 - Addition of second agent
 - Chemotherapy
 - New drug (study or compassionate use)



Kim SY, Halmos B. *Lung Cancer Manag.* 2020;9(3):LMT36. Planchard D, et al. *Ann Oncol.* 2018;29(suppl 4):iv192-iv237.

EGFR

What are the resistance mechanisms to osimertinib?



What other possibilities with availeable drugs in C797 mutated patients?


- Osimertinib + 1st gen EGFR TKI (gefitinib) ¹
 - A rapid decrease of the C797 subclone was noted but of short duration...
- Osimertinib + brigatinib + bevacizumab²
 - A partial remission was observed duration?
- Cetuximab + brigatinib ^{3, 4}
 - Invitro and animals...
 - 1 PR out of 10 patients, but 5 SD
- => situation is not brilliant...

Zhao J, Zou M, Lv J, Han Y, Wang G, Wang G. Effective treatment of pulmonary adenocarcinoma harboring triple EGFR mutations of L858R, T790M, and cis-C797S by osimertinib, bevacizumab, and brigatinib combination therapy: a case report. Onco Targets Ther. 2018 Sep 6;11:5545-5550. doi: 10.2147/OTT.S170358.
 Uchibori, K., Inase, N., Araki, M. et al. Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer. Nat Commun 8, 14768 (2017). <u>https://doi.org/10.1038/ncomms14768</u>

^{1.} Arulananda S, Do H, Musafer A, Mitchell P, Dobrovic A, John T. Combination Osimertinib and Gefitinib in C797S and T790M EGFR-Mutated Non-Small Cell Lung Cancer. J Thorac Oncol. 2017 Nov;12(11):1728-1732. doi: 10.1016/j.jtho.2017.08.006.

Wang Y, Yang N, Zhang Y, Li Li, Han R, Zhu M, Feng M, Chen H, Lizaso A, Qin T, Liu X, He Y. Effective Treatment of Lung Adenocarcinoma Harboring EGFR-Activating Mutation, T790M, and cis-C797S Triple Mutations by Brigatinib and Cetuximab Combination Therapy. J Thorac Oncol. 2020 Aug;15(8):1369-1375. doi 10.1016/j.jtho.2020.04.014.

Progressing Towards a Fourth-Generation of *EGFR* Inhibitors?^{1–3}



BID, twice daily; EGFR, epidermal growth factor receptor; EGFR-TKI, epidermal growth factor receptor tyrosine kinase inhibitor; QD, once daily; SEM, standard error of the mean; WT, wild type 1. Zhou W, et al. Nature 2009;462:1070–4; 2. Schalm S, et al. Presented at: European Society for Medical Oncology Asia Congress 2020; 20–22 November 2020; 3. Jia Y, et al. Nature 2016;534:129–32


Overc resista

С

Recei


JBJ-040125-02

- Able to inhibit cell proliferation and EGFR L858R/T790M/C797S signaling *in vitro* and *in vivo*
- Osimertinib may enhance the binding of JBJ-040-125-02
- Combination of Osimertinib and JBJ-040-125-02 may potentially increase inhibition of cell growth and increase apotosis.
- Relatively low bioavailability



To and Janne et al Cancer Discovery ePub May 15 2019

What are the resistance mechanisms to osimertinib?



Tuble 5. Summary of prognostic impact of Exon26 insertions compared to other genotypes.								
	Range Median OS	Range Median PFS	Range ORR					
	(months)	(months)	(%)					
TKIs								
Exon 20ins	4.8-19	1.4-3.0	0–20%					
	6 studies	8 studies	7 studies					
	177 patients (range 11–67)	183 patients (range 11– 67)	194 patients (range 11– 67)					
Classic <i>EGFR</i> m (del 19 or L858R)	19.6–27.7	8.5-15.2	27.4-84%					
	3 studies	3 studies	5 studies					
	501 patients (range 37-278)	501 patients (range 37– 278)	1193 patients (range 37– 692)					
Т790М	13.5–27.7	1.0-2.9	0–25%					
	3 studies	3 studies	4 studies					
	67 patients (range 14-30)	67 patients (range 14-30)	114 patients (range 14– 47)					
Wild-type	10.4–21	2	16.50%					
	2 studies	1 study	1 study					
	990 patients (range 20-88)	1261 patients (range 15– 39)	1261 patients (range 20– 102)					

Table 3. Summary of prognostic impact of Exon20 insertions compared to other genotypes.

Poziotinib

- Poziotinib (HMB781-36B) is an orally available, irreversible covalent TKI.
- Multi-cohort phase II ZENITH20
- Of the 79 patients participating in ZENITH20, twelve patients remained on treatment with median follow up of 9.2 months.
- FDA grants fast track status for poziotinib in March 2021
- ORR 27%
- PFS 5.5 mo

• OS 15 mo

- 30 20 Sum of Diameter 10 -10 н. -20 . **Best % Change from Baseline** -30 -40 -50 -60 -70 Best Overall Response -80 Partial Response 91% (72/79) had tumour shrinkage Stable Disease 3% (2/79) tumour volume increased Progressive Disease Not Evaluable Median % tumour reduction = 25.5% * Treatment Ongong
- 1. Remon J, Hendriks LEL, Cardona AF, Besse B. EGFR exon 20 insertions in advanced non-small cell lung cancer: A new history begins. Cancer Treat Rev. 2020 Nov;90:102105. doi: 10.1016/j.ctrv.2020.102105.
- 36MO Sacher A, Le X, Cornelissen R, et al. Safety, tolerability and preliminary efficacy of poziotinib with twice daily strategy in EGFR/HER2 Exon 20 mutant non-small cell lung cancer. ESMO Targeted Anticancer Therapies (TAT) Virtual Congress (1-2 March 2021)

Mobocertinib (TAK-788)

- Irreversible covalent TKI, excellent preclinical activity in this situation ^{1, 2}
- Phase 1 study, 73 patients interesting responses in ex 20 ins ³
- Phase 2 study, 70 previously treated NSCLC patients harboring EGFR ex20ins mutations ³
- ORR and DCR were 44% and 86% respectively for the 160 mg dose
- Phase 3 ongoing
- Received FDA approval in this indication in September 2021


- 1. Mobocertinib (TAK-788): A Targeted Inhibitor of EGFR Exon 20 Insertion Mutants in Non–Small Cell Lung Cancer. F Gonzalvez, V M. Rivera et al. July 2021 Vol 11, Issue 7, DOI: 10.1158/2159-8290.CD-20-1683
- 2. Zhang SS, Zhu VW. Spotlight on Mobocertinib (TAK-788) in NSCLC with EGFR Exon 20 Insertion Mutations. Lung Cancer (Auckl). 2021 Jul 12;12:61-65. doi: 10.2147/LCTT.S307321.
- Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer with <i>EGFR</i> Exon 20 Insertion Mutations from a Phase I/II Trial. Riely GJ, Jänne PA Cancer Discov. 2021 Jul; 11(7):1688-1699.

Amivantamab


- Amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR-MET, has shown preclinical activity in TKI-sensitive *EGFR*-mutated NSCLC models and in an ongoing first-in-human study in patients with advanced NSCLC¹.
- 50 pts with exon20ins mutations
- 14 responders, median duration of response was 10 months (1–16), with ongoing responses in 9 pts
- Recieves FDA approval in this indication in May 2021

^{1.} Keunchil Park, Amivantamab (JNJ-61186372), an anti-EGFR-MET bispecific antibody, in patients with EGFR exon 20 insertion (exon20ins)-mutated non-small cell lung cancer (NSCLC). DOI: 10.1200/JCO.2020.38.15_suppl.9512 *Journal of Clinical Oncology* 38, no. 15_suppl (May 20, 2020) 9512-9512.

What are the resistance mechanisms to osimertinib?



c-MET alterations



Nature Reviews | Cancer

1. MET exon14 alteration 3~4%

- It prevents the MET receptor from being degraded, resulting in increased MET activity
- Recognized as oncogenic-driver mutation and targeted therapy (Capmatinib and Tepotinib) have been already established as standard therapy.

2. De novo MET amplification, 1~5%

• No standard therapy for MET+ NSCLC, although it was demonstrated as potential oncogenic driver gene alteration.

3. TKI-resistant EGFR mt NSCLC, 7~15%

• MET-i +/- EGFR-TKI treatment strategy is under evaluation both for TKI resistance and naïve EGFR mt NSCLC. (e.g, amivantamab+TKI, Tepotinib+TKI, and Savolitinib+TKI)

Comoglio, P.M., Trusolino, L. & Boccaccio, C. Nat Rev Cancer 18, 341–358 (2018). Camidge DR, et.al, JTO. 2021 Jun;16(6):1017-1029, Drilon A, et.al, JTO 2017;12: 15-26, Alessandro Leonetti, Br J Cancer. 2019 Oct;121(9):725-737.

New MET inhibitors

The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE

Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung Cancer


J. Wolf, T. Seto, J.-Y. Han, N. Reguart, E.B. Garon, H.J.M. Groen, D.S.W. Tan, T. Hida, M. de Jonge, S.V. Orlov, E.F. Smit, P.-J. Souquet, J. Vansteenkiste, M. Hochmair, E. Felip, M. Nishio, M. Thomas, K. Ohashi, R. Toyozawa, T.R. Overbeck, F. de Marinis, T.-M. Kim, E. Laack, A. Robeva, S. Le Mouhaer, M. Waldron-Lynch, B. Sankaran, O.A. Balbin, X. Cui, M. Giovannini, M. Akimov, and R.S. Heist, for the GEOMETRY mono-1 Investigators*

ORIGINAL ARTICLE

Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations

P.K. Paik, E. Felip, R. Veillon, H. Sakai, A.B. Cortot, M.C. Garassino, J. Mazieres, S. Viteri, H. Senellart, J. Van Meerbeeck, J. Raskin, N. Reinmuth, P. Conte, D. Kowalski, B.C. Cho, J.D. Patel, L. Horn, F. Griesinger, J.-Y. Han, Y.-C. Kim, G.-C. Chang, C.-L. Tsai, J.C.-H. Yang, Y.-M. Chen, E.F. Smit, A.J. van der Wekken, T. Kato, D. Juraeva, C. Stroh, R. Bruns, J. Straub, A. Johne, J. Scheele, J.V. Heymach, and X. Le


Tumor Responses to Capmatinib and Tepotinib.



Wolf J et al. N Engl J Med 2020;383:944-957 Paik PK et al. N Engl J Med 2020;383:931-943 Xiuning, Paik et al, Tepotinib in patients (pts) with advanced non-small cell lung cancer (NSCLC) with MET amplification (METamp), JCO 2021 39:15 suppl, 9021-9021

MET amplification Phase Ib TATTON: Osimertinib + Savolitinib


- 138 patients received osimertinib plus savolitinib 600 mg
- Objective partial responses were observed in 48%
- Responses were not related to cocommitant T790M status
- But serious adverse events an 2 deaths were observed



Drilon A, et al. J Thorac Oncol. 2017;12:15-26.
 Piotrowska Z, et al. ASCO 2017. Abstract 9020.
 Yang Z, et al. Int J Biol Sci. 2018;14:204-216.
 Ahn MJ, et al. WCLC 2017. Abstract 8985.

Antibody Drug Conjugate in MET amp


Telisotuzumab-Vedotin (Teliso-V)



 IASLC
 2021 World Conference on Lung Cancer

 SEPTEMBER 8 - 14, 2021 I WORLDWIDE VIRTUAL EVENT

What are the resistance mechanisms to osimertinib?



Non selective **HER2** thyrosin kinase inhibitors

- Afatinib
- Dacomitinib
- Neratinib

Selective HER2 thyrosin kinase inhibitors

- Poziotinib
- Pyrlotinib
- Tarloxotinib
- Mobocertinib

Monoclonal antibodies against HER2

Trastuzumab

Antibody Drug Conjugates (ADCs)

- Trastuzumab emtansine (T-DM1)
- Trastuzumab-deruxtecan (T-Dxd)

Target mostly HER 2 mutations


Trastuzumab

- Trastuzumab is a monoclonal antibody that binds to the extracellular domain of the HER2 receptor well known in breast cancer.
- In a retrospective study of 57 patients reported an ORR of 50% and a median PFS of 4.8 months in the chemotherapy and trastuzumab combination group.
- BUT in prospective studies, a lack of response trastuzumab + chemotherapy compared to chemotherapy alone has been consistently observed regardless of the HER2 'level' of positivity as determined by IHC or FISH.
- The combination of trastuzumab with pertuzumab (HER2 dimerization blocker) has shown limited activity in the phase IIa MyPathway basket trial.

Mazières J, Barlesi F, Filleron T, et al. Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort. Ann Oncol. 2016;27(2):281-286 Krug LM, Miller VA, Patel J, et al. Randomized phase II study of weekly docetaxel plus trastuzumab versus weekly paclitaxel plus trastuzumab in patients with previously untreated advanced nonsmall cell lung carcinoma. Cancer. 2005;104(10):2149-2155

Hainsworth JD, Meric-Bernstam F, Swanton C, et al. Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from MyPathway, an open-label, phase IIa multiple basket study. J Clin Oncol. 2018;36(6):536-542.

Trastuzumab emtansine (T-DM1)




Three of four responders had HER2 amplification and two patients had a concomitant HER2 mutation.

TRAEs in >10% of patients were mainly grade 1 or 2 events and included elevated AST or ALT, thrombocytopenia, fatigue, infusion reaction, nausea, weight loss, maculopapular rash, anorexia, epistaxis, and anemia. There was only 1 patient with treatment-related grade 3 anemia. No grade 4 or 5 AEs were reported. There were no dose reductions or discontinuations due to TRAEs.

Trastuzumab-deruxtecan (T-Dxd) T-DXd Was Designed With 7 Key Attributes

T-DXd is an ADC composed of 3 components^{1,2}:

- A humanized anti-HER2 IgG1 mAb with the same amino acid sequence as trastuzumab, covalently linked to:
- A topoisomerase I inhibitor payload, an exatecan derivative, via
- A tetrapeptide-based cleavable linker



	Payload mechanism of action: topoisomerase I inhibitor ^{a,1,2}
	High potency of payload a,1,2
	High drug to antibody ratio $\approx 8^{a,1,2}$
	Payload with short systemic half-life a,1,2
	Stable linker-payload a,1,2
HO CH ₃	Tumor-selective cleavable linker a,1,2
Inhibitor payload 1f derivative)	Bystander antitumor effect a,1,4


The payload DXd is highly membrane-permeable compared to that of T-DM1. The bystander effect is observed only in cells neighbouring HER2-positive cells, indicating low concern in terms of systemic toxicity.

^aThe clinical relevance of these features is under investigation.

1. Nakada T, et al. Chem Pharm Bull (Tokyo). 2019;67(3):173-185. 2. Ogitani Y, et al. Clin Cancer Res. 2016;22(20):5097-5108. 3. Trail PA, et al. Pharmacol Ther. 2018;181:126-142. 4. Ogitani Y, et al. Cancer Sci. 2016;107(7):1039-1046.




Trastuzumab Deruxtecan in Patients With HER2 Mut Destiny lung



- 91 patients with HER2m NSCLC were enrolled and treated with T-DXd
- 15 patients (16.5%) remain on treatment to date
- 76 patients (83.5%) discontinued, primarily for progressive disease (37.4%) and adverse events (29.7%)

What are the resistance mechanisms to osimertinib?



Amivantamab EGFR-MET bispecific AB + Lazertinib 3rd gen EGFR TKI




Amivantamab Monotherapy and in Combination with Lazertinib in Post-osimertinib EGFR-mutant NSCLC: Analysis from the CHRYSALIS Study

<u>Natasha B. Leighl</u>¹, Catherine A. Shu², Anna Minchom³, Enriqueta Felip⁴, Sophie Cousin⁵, Byoung Chul Cho⁶, Keunchil Park⁷, Ji-Youn Han⁸, Michael Boyer⁹, Chee Khoon Lee¹⁰,

CHRYSALIS Study Design

(NCT02609776)



Efficacy: AMI Monotherapy and AMI + LAZ

(descriptive cross-cohort analysis)




	AMI (n=121)	AMI + LAZ (n=45)		
Best response ^a	27%	36%		
Confirmed ORR' (95% CI)	19% (12-27)	36% (22-51)		
CR	0	1 (2%)		
PR	23 (19%)	15 (33%)		
SD	53 (44%)	14 (31%)		
PD	39 (32%)	11 (24%)		
NE	6 (5%)	4 (9%)		
mDOR (95% CI)	5.9 mo (4.2-12.6)	9.6 mo (5.3–NR)		
CBR (95% CI)	48% (39–57)	64% (49-78)		
mPFS (95% CI)	4.2 mo (3.2-5.3)	4.9 mo (3.7–9.5)		
mF/U (range)	6.9 mo (0.7-38.6)	11.1 mo (1.0-15.0)		

'ORR among patients with identified EGFR/MET-based osimertinib resistance was 18% for AMI and 47% for AMI + LAZ¹

Addition of lazertinib to amivantamab was associated with numerically higher objective response rate and longer duration of response after progression on osimertinib

40%

Heavily Pretreated: Antitumor Activity of Amivantamab + Lazertinib



Among 47 efficacy-evaluable^a patients at a median follow-up of 4.5 mo (range, 0.3–9.7):

- ORR = 21% (95% CI, 11–36)
- CBR = 51% (95% CI, 36–66)
- Median time on treatment = 3.7 mo (range, 0.03–9.7)
- Responses observed early
- mTTR = 1.5 mo (range, 1.3-4.2)
- 10/10 patients who responded are progression-free and remain on treatment
- 10/26 patients with stable disease remain on treatment (longest at 9.6+ mo)


Datopotamab Deruxtecan in NSCLC with Actionable genomic alterations



Efficacy of Datopotamab Deruxtecan (Dato-DXd) in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) and Actionable Genomic Alterations (AGAs): Preliminary Results From the Phase 1 TROPION-PanTumor01 Study

Edward B. Garon,¹ Melissa L. Johnson,² Aaron E. Lisberg,¹ Alexander Spira,³ Noboru Yamamoto,⁴ Rebecca S. Heist,⁵ Jacob M. Sands,⁸ Kiyotaka Yoh,⁷


- Trop-2 is a highly expressed antigen on NSCLCs.
- Here we study patients with pretreated mut activators.



Cleavable tetrapeptide-based linker

Topoisomerase l inhibitor payload (DXd)


TROPION-PanTumor01 Study Design



NSCLC With AGAs: Antitumor Activity

Best Overall Response (BICR)					
Patients ^a	Dato-DXd n=34				
ORR, n (%)	12 (35)				
CR	0				
PR	12 (35)				
SD, n (%)	14 (41)				
Non-CR/PD, n (%)	2 (6)				
PD, n (%)	2 (6)				
NE, n (%)	4 (12)				
DOR, median (95% CI), mo	9.5 (3.3-NE)				


 Clinical activity was observed in EGFR (Ex19del, L858R) including after osimertinib and across other AGAs




Data outoff: April 8, 2024

Lack of Efficacy With Immune Checkpoint Inhibition in EGFR Mutation–Positive NSCLC

 Phase II study of pembrolizumab in patients with PD-L1–positive EGFR-mutated advanced NSCLC (planned N = 25); stopped for futility at 11 patients



EGFR Mutations: Anti-PD-L1 in Combination With Chemotherapy and Antiangiogenic Therapy




Data cut-off: 22 January 2018; asensitising EGFR mutations are defined as exon 19 deletions or Leu858Arg mutations

ABCP, atezolizumab + bevacizumab + carboptatin + paclitaxel; ACP, atezolizumab + carboptatin + paclitaxel; BCP, bevacizumab + carboptatin + paclitaxel; CI, confidence interval; EGFR, epidermal growth factor receptor; HR, hazard ratio;

PD-L1, programmed cell death ligand-1; NE, not estimable; TKI, tyrosine kinase inhibitor

1. Reck M, et al. Lancet Respir Med 2019;7:387-401

EML-Alk translocated patients Mechanisms and potential strategies to overcome acquired resistance to ALK inhibition



Lovly ASCO Educ Book 2015

EML-Alk translocated patients

Next generation ALK and ROS1 Inhibitors : Better CNS penetration, more potent, active against resistance kinase domain mutations

Mutation status	Crizotinib	Ceritinib	Alectinib	Brigatinib	Lorlatinib
Parental Ba/F3	763.9	885.7	890.1	2774.0	11293.8
EML4-ALK V1	38.6	4.9	11.4	10.7	2.3
EML4-ALK C1156Y	61.9	5.3	11.6	4.5	4.6
EML4-ALK I1171N	130.1	8.2	397.7	26.1	49.0
EML4-ALK I11715	94.1	3.8	177.0	17.8	30.4
EML4-ALK	51.4	1.7	33.6*	6.1	11.5
EML4-ALK F1174C	115.0	38.0"	27.0	18.0	8.0
EML4-ALK L1196M	339.0	9.3	117.6	26.5	34.0
EML4-ALK L1198F	0.4	196.2	42.3	13.9	14.8
G1202R	381.6	124.4	706.6	129.5	49.9
EML4-ALK G1202del	58.4	50.1	58.8	95.8	5.2
EML4-ALK D1203N	116.3	35.3	27.9	34.6	11.1
EML4-ALK E1210K	42.8	5.8	31.6	24.0	1.7
EML4-ALK G1269A	117.0	0.4	25.0	ND	10.0
EML4-ALK 01203N+F1174C	338.8	237.8	75.1	123.4	69.8
EML4-ALK D1203N+E1210K	153.0	97.8	82.8	136.0	26.6

Gainor et al. Cancer Discovery 2016

IC50 ≤ 50 nM IC50 > 50 <200 nM

1C50 ≥ 200 nM

ALK G1202R Lorlatinib > Ropotrectinib

ROS1 G2032R Ropotrectinib > Lorlatinib

Table 1. Ropotrectinib Potently Inhibited WT and Mutant ALK/ROS1/TRK in Ba/F3 Cell Proliferation IC 50 (nM


	EML4	-ALK V1		CD74-ROS	51	LMN	A-TRKA	ETV	6-TRKB		ETV6-TR	кс
Inhibitor	WT	G1202R	WT	G2032R	02033N	WT	G595R	WT	G639R	WT	G623R	G623
Ropotrectinib	27	63.6	<0.2	3.3	1.3	<0.2	0.4	<0.2	0.6	<0.2	3	1.4
Crizotinib	55.7	400	14.6	266.2	200.9							
Ceritinib	7.1	965	42.8	1813	169.2							
Alectinib	11.6	417	12.0									
Brigatinib	10.9	190.5	21	1172	128.4							
Lorlatinib	0.5	41.5	0.2	160.7	3.3							
Ensartinib			39.5	371.8	401.9							
Entrectinib			10.5	1813	169.2	0.5	705	<0.5	1384	0.6	1623	1351
Larotrectinib						4	1024	10.9	3000	10.2	3293	742.3

Drilon et al ASCO 2018

EML-Alk translocated patients



CROWN trial of Lorlatinib vs Crizotinib : Primary Endpoint PFS by BICR




	Lorlatinib (n=149)	Crizotinib (n=147)				
Patients with event, n (%)	41 (28)	86 (59)				
Median PFS, months (95% CI)	NE (NE–NE)	9.3 (7.6-11.1)				
HR (95% CI) 1-sided P value*	0.28 (0.19-0.41) <0.001					
*By stratified log-rank test.						

Solomon et al. ESMO 2020

BICR, blinded independent central review; CI, confidence interval; HR, hazard ratio; NE, not estimable; PFS, progression-free survival

EML-Alk translocated patients

Treatment algorithms for ALK+ NSCLC



Current Treatment Paradigm for Molecular Biomarker– Positive Advanced NSCLC

Current global treatment guideline recommendations for advanced NSCLC

